Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium lactis + lactobacillus acidophilus
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This synbiotic preparation is a combination of the probiotic bacterial strains *Bifidobacterium lactis* and *Lactobacillus acidophilus*. In preclinical research involving spontaneously hypertensive rats (SHR), the oral administration of this microbial therapy demonstrated significant antihypertensive activity. The mechanism of action is characterized by the modulation of the gut microbiome and the subsequent activation of the peroxisome proliferator-activated receptor (PPAR) signaling pathway. Specifically, the treatment leads to the upregulation of PPARβ and PPARγ expression within the ileum, which is associated with a reduction in systemic blood pressure. This approach highlights the potential of live biotherapeutic products to manage cardiovascular conditions through the gut-heart axis.
- Other names
- Bifidobacterium animalis subsp. lactis + Lactobacillus acidophilusB. lactis + L. acidophilus
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on bifidobacterium lactis + lactobacillus acidophilus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium lactis + lactobacillus acidophilus.